EMEA-000878-PIP02-11 - paediatric investigation plan

colestilan

Key facts

• Invented name:
  • BindRen
  • BindRen
• Active Substance:
  colestilan
• Therapeutic area:
  Uro-nephrology
• Decision number:
  P/207/2011
• PIP number:
  EMEA-000878-PIP02-11
• Pharmaceutical form(s):
  • Granules
  • Film-coated tablet
• Condition(s) / indication(s):
  Treatment of hyperphosphataemia
• Route(s) of administration:
  Oral use
• Contact for public enquiries:

  Mitsubishi Pharma Europe Ltd

  United Kingdom; E-mail: [e-mail]; [phone]; [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  01/09/2011

Decision

P/207/2011: EMA decision of 1 September 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for colestilan (EMEA-000878-PIP02-11)

AdoptedReference Number: EMA/697254/2011